Evidence map›Paper›PMID 40331902›Full record

ArticleACS applied materials & interfaces2025

Refillable Intraocular Drug-Eluting Implant.

Hyeonji Kim, Nae-Won Kang, Roger Wise, Akira Feliz, David Myung, Charles DeBoer

Abstract read
In one paragraph

Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hyeonji KimDepartment of Ophthalmology, Byers Eye Institute at Stanford University, School of Medicine, Palo Alto, California 94304, United States.
Nae-Won KangDepartment of Ophthalmology, Byers Eye Institute at Stanford University, School of Medicine, Palo Alto, California 94304, United States.
Roger WiseDepartment of Radiology, School of Medicine, Stanford University, Palo Alto, California 94304, United States.
Akira FelizDepartment of Ophthalmology, Byers Eye Institute at Stanford University, School of Medicine, Palo Alto, California 94304, United States.
David MyungDepartment of Ophthalmology, Byers Eye Institute at Stanford University, School of Medicine, Palo Alto, California 94304, United States.
Charles DeBoerDepartment of Ophthalmology, Byers Eye Institute at Stanford University, School of Medicine, Palo Alto, California 94304, United States.ORCID 0000-0003-1308-0583

Funding

Stanford Vision Research CoreP30EY026877 · NEI · STANFORD UNIVERSITY · PI TIRIN MOORE · 2017 to 2026
$8.0M
Lens Capsule Based Extended Drug Delivery DeviceK08EY036955 · NEI · STANFORD UNIVERSITY · PI Charles Meno Theodore DeBoer · 2025 to 2026
$516k
NEI NIH HHS K08 EY036955NEI NIH HHS P30 EY026877
6 · The paper itself

Abstract

The increasing incidence of ophthalmic diseases has led the need for multiple dosage regimens, which can cause patient discomfort and noncompliance due to the frequency of medication administration. Still, ophthalmic drug delivery methods, such as eye drops and intravitreal injection, pose challenges, such as poor bioavailability, short half-life, and patient compliance. In this study, we introduce a novel refillable intracapsular drug-eluting reservoir for the long-term management of ocular diseases. This device, made of medical-grade silicone and stainless steel, has features to contour the lens capsule to facilitate microincisional implantation. Rheological and mechanical analyses of the silicone revealed the optimized conditions for the device construction and its application compliance for ocular intracapsular implantation. Furthermore, in vitro release studies exhibit controlled drug release, the kinetics of which were along with Fickian diffusion, while ex vivo implantation testing shows that the device can be easily delivered and placed at the time of cataract surgery. Taken altogether, the developed implant holds significant potential for improving therapeutic outcomes while offering a practical surgical application and compliance of patients.

Indexed as

Drug Delivery SystemsDrug ImplantsAnimalsDrug LiberationHumansSiliconesDrug ImplantsSiliconescataract surgerydrug delivery systemintraocular implantocular treatmentsustained release

Identifiers

PMID40331902
PMCPMC12998487

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.